PZH2113

PZH2113 is an orally bioavailable, small molecule inhibitor of Bruton's tyrosine kinase (BTK) developed by Zhangzhou Pientzehuang Pharmaceutical. As a Class 1 innovative drug in China, it is currently undergoing Phase 1 clinical evaluation for the treatment of various relapsed or refractory B-cell malignancies. The drug is designed to selectively inhibit BTK, a critical mediator of the B-cell receptor (BCR) signaling pathway that drives the survival, proliferation, and migration of malignant B cells. PZH2113 is primarily being studied in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL), including diffuse large B-cell lymphoma (DLBCL), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and Waldenström macroglobulinemia (WM).